| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
CDK8 (IC50 ~200 nM); recombinant CDK8 (IC50 ~0.5 μM); recombinant CDK19 (IC50 >30 μM); IL-10
BRD6989 targets CDK8 and CDK19. It acts as a selective inhibitor, binding to the kinase complexes of CDK8 and CDK19. By inhibiting these kinases, the compound modulates the activity of the Mediator complex, which is involved in transcriptional regulation. This inhibition leads to the upregulation of IL-10, an anti-inflammatory cytokine. |
|---|---|
| ln Vitro |
Using BRD6989 (0-100 μM; 48 hours) to ablate BMDCs results in an EC50 trajectory of 1 μM for IL-10 production [1]. IFNγ-stimulated BMDCs are inhibited at Ser727 by BRD6989 (0.6, 1.7, 5, 15 μM). After stimulating BMDMs, BRD6989 (5 μM; ~2 hours) differentially suppresses STAT1–STAT2 activity and phosphorylation of the NF-κB activation domain [1]. BRD6989 (^2 hours; 5 µM). 24 hours) increases the synthesis of IL-10 and activator in mouse dendritic cells and macrophages [1].
In vitro, BRD6989 has been shown to be a potent inhibitor of CDK8 with an IC50 of approximately 200 nM. It inhibits the kinase activity of recombinant CDK8 or CDK19 complexes. The compound upregulates IL-10 production in bone marrow-derived dendritic cells. It also inhibits STAT1 phosphorylation at S727. |
| ln Vivo |
In vivo, BRD6989 is being evaluated for its immunomodulatory effects. By upregulating IL-10, the compound has the potential to suppress inflammatory responses. It may be useful for studying the role of CDK8 in inflammation and immunity.
|
| Enzyme Assay |
In vitro enzyme or receptor binding (non-cell) assays for BRD6989 involve measuring its direct inhibition of CDK8 kinase activity. The assay uses a purified recombinant CDK8/cyclin C complex and a peptide substrate in the presence of ATP. The phosphorylation of the substrate is measured using a radioactive or fluorescent method. The compound is incubated with the enzyme and substrate, and the decrease in phosphorylation is measured to determine the IC50.
|
| Cell Assay |
In vitro cell-based assays for BRD6989 are performed using macrophages and dendritic cells. Cells are treated with the compound, and IL-10 production is measured by ELISA. STAT1 phosphorylation is assessed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for BRD6989 are conducted using mouse models of inflammation and immunity. The compound is administered, and its effects on cytokine production and immune cell function are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of BRD6989 have been characterized to support its use as a research tool. The compound has a molecular weight of 260.34 and a formula of C₁₆H₁₆N₄. It is soluble in DMSO. Specific PK parameters, such as half-life and bioavailability, are determined in preclinical studies via LC-MS/MS analysis of plasma samples.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for BRD6989 are typical of a research compound. It is generally well-tolerated at effective doses. The safety profile is being evaluated in the context of its use as a research tool to study CDK8 biology.
|
| References | |
| Additional Infomation |
2-Amino-6-methyl-4-(3-pyridyl)-5,6,7,8-tetrahydroquinoline-3-nitrile is a member of the bipyridine class of compounds.
Other information: BRD6989 is a research compound used to study the role of CDK8 in inflammation and immunity. It is available from chemical suppliers for preclinical research purposes. |
| Molecular Formula |
C16H16N4
|
|---|---|
| Molecular Weight |
264.332
|
| Exact Mass |
264.137
|
| Elemental Analysis |
C, 72.70; H, 6.10; N, 21.20
|
| CAS # |
642008-81-9
|
| Related CAS # |
642008-81-9
|
| PubChem CID |
3835861
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
496.6±45.0 °C at 760 mmHg
|
| Flash Point |
254.2±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.640
|
| LogP |
3.69
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1=C(N=C2CCC(C)CC2=C1C1=CN=CC=C1)N)#N
|
| InChi Key |
QSYBDNXNOJIKML-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H16N4/c1-10-4-5-14-12(7-10)15(11-3-2-6-19-9-11)13(8-17)16(18)20-14/h2-3,6,9-10H,4-5,7H2,1H3,(H2,18,20)
|
| Chemical Name |
2-amino-6-methyl-4-pyridin-3-yl-5,6,7,8-tetrahydroquinoline-3-carbonitrile
|
| Synonyms |
BRD-6989; BRD6989; BRD 6989
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25~30 mg/mL (94.6~113.5 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7831 mL | 18.9157 mL | 37.8315 mL | |
| 5 mM | 0.7566 mL | 3.7831 mL | 7.5663 mL | |
| 10 mM | 0.3783 mL | 1.8916 mL | 3.7831 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
